Fig. 2: LyomRNA-Delta elicits a potent immune response and protects mice from infection by Delta viruses. | Cell Discovery

Fig. 2: LyomRNA-Delta elicits a potent immune response and protects mice from infection by Delta viruses.

From: Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2

Fig. 2: LyomRNA-Delta elicits a potent immune response and protects mice from infection by Delta viruses.The alternative text for this image may have been generated using AI.

a BALB/c mice (n = 10) were intramuscularly injected with saline or immunized twice at a dose of 5 μg or 10 μg at an interval of 14 days. Plasma samples were collected on D14 after the second dose to detect the Delta RBD-specific binding antibody titers. b–f K18-hACE2 transgenic mice were injected with saline, blank LNP (LNP without mRNA), or intramuscularly inoculated with 5 μg or 10 μg of LyomRNA-Delta vaccine twice at an interval of 14 days, and two weeks after the second dose, 2.5 × 103 PFUs of SARS-CoV-2 Delta were administered to the animals intranasally. b Live SARS-CoV-2 Delta 50% neutralization titers 14 days after the second dose. c Animal survival curves after challenge. All blank LNP animals died or were euthanized 7 days after the challenge. d–f The virus load in the lungs (d), virus load in the brain (e), and pathology score (f) were evaluated 7 and 14 days after the challenge. Data are presented as the geometric means ± 95% confidence interval (a, b), geometric means ± geometric SD (d, e), or means ± SEM (f). a, b Doses were compared by a two-sided Mann–Whitney test. f Groups were compared to mock by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons test. ns, not significant. *P < 0.05, ***P < 0.001. The horizontal dashed line marks the lower limit of detection (LLOD). Values below the LLOD were set to half the LLOD.

Back to article page